Navigation Links
Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172
Date:6/4/2008

at our website at http://www.nuvelo.com or by phoning 650-517-8000.

This press release contains "forward-looking statements," which include statements regarding the timing, progress and anticipated completion of Nuvelo's clinical stage and research programs, the anticipated availability of top-line data, projected operating expenses and cash usage and the potential benefits that patients may experience from the use of our clinical stage compounds, which statements are hereby identified as "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on our management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, uncertainties relating to drug discovery and the regulatory approval process; clinical development processes; enrollment rates for patients in our clinical trials; changes in relationships with strategic partners and dependence upon strategic partners for the performance of critical activities under collaborative agreements; and the impact of competitive products and technological changes. These and other factors are identified and described in more detail in Nuvelo's filings with the SEC, including without limitation Nuvelo's quarterly report on Form 10-Q for the quarter ended March 31, 2008 and subsequent filings. We disclaim any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE Nuvelo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172
2. Nuvelo Announces Preclinical Data for NU206 Demonstrating Potent Therapeutic Activity in Oral Mucositis Models
3. Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
4. Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
5. Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
6. Nuvelo Announces Alfimeprase SONOMA-2 Catheter Occlusion Data Presentation Webcast and Conference Call
7. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
8. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
9. Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
10. Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors
11. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 ... Market Research "Endoscopy Devices Market (Endoscopes, Endoscopic Operative Devices, ... Growth, Trends and Forecast, 2013-2019" the global endoscopy devices ... and is expected to grow at a CAGR of ... value of USD 36.9 billion in 2019. ...
(Date:7/11/2014)... , July 11, 2014  Veran ... company, announced today the positive, cost-effective final ... innovative SPiNPerc™ procedure. The SPiNPerc endobronchial percutaneous ... a percutaneous approach to biopsy when a ... patients and physicians experience positive financial outcomes ...
(Date:7/11/2014)... 2014 Neurelis, Inc. ("Neurelis") today announced an ... option held by Biotie to purchase Neurelis, clearing the ... (intranasal diazepam) for pediatric and adult epilepsy patients who ... year, Biotie has advanced the development program for NRL-1 ... clinical work required for NDA submission to the FDA.  ...
Breaking Medicine Technology:Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Veran Medical Publishes Lung Cancer Patient Management Study 2Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
... of Hypertension,s Twenty-Third ... Annual Scientific Meeting - A cumulative forty-five percent ... of BENICAR(R) (olmesartan medoxomil), and BENICAR HCT(R) (olmesartan medoxomil/hydrochlorothiazide) achieved ... normotension (< 120/80 mm Hg) (placebo:1.4%)., - Eight out of 10 (cumulative ...
... Florida and Scripps Research in La ... ... and LA JOLLA, Calif., May 14 /PRNewswire-,FirstCall/ -- Poniard Pharmaceuticals, Inc. ... Scripps Research,Institute, a non-profit biomedical research organization, today announced,that an agreement ...
Cached Medicine Technology:New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 2New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 3New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 4New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 5New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 6New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R) 7Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute 2Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute 3Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute 4
(Date:7/14/2014)... California (PRWEB) July 14, 2014 ... to reach USD 4,285.1 million by 2020 growing ... new study by Grand View Research, Inc. Steady ... biology for bioinformatics R&D programs designed for sequencing ... number of clinical studies in pharmacogenomics and pharmacokinetics ...
(Date:7/14/2014)... Austin, TX (PRWEB) July 14, 2014 Kenn ... practices recently. The video is meant to describe the business ... real estate broker and national speaker – Kenn Renner – ... of branding, marketing, and goal setting techniques. , Investing in ... extra money. Some people do it as their career, while ...
(Date:7/14/2014)... NATURALLY, DANNY SEO, a new magazine ... with a Fall issue that hits newsstands nationwide on ... the healthy, natural and good for you life with ... beauty, travel, home, and entertaining all through Danny’s unique ... “Instead of gimmicky weight loss tips and fluffy celebrity ...
(Date:7/14/2014)... (PRWEB) July 14, 2014 According to the ... is a helpful guide that features a series of new ... in its review that this book can help readers understand ... of high blood pressure, and effective methods to control ... are reviewed now by Vkool, was penned by Ken Burge, ...
(Date:7/14/2014)... July 14, 2014 Vaginal Mesh ... against seven different pelvic mesh manufacturers in the U.S. ... & Schulte LLC. The federal complaints are pending against ... 2327), American Medical Systems (MDL No. 2325), and C.R. ... there are 58,262 Vaginal Mesh lawsuit claims pending, according ...
Breaking Medicine News(10 mins):Health News:Global Computational Biology Market by Application (Cellular & Biological Simulation), by Services (In-house, Contract) is Expected to Reach USD 4,285.1 Million by 2020 2Health News:Global Computational Biology Market by Application (Cellular & Biological Simulation), by Services (In-house, Contract) is Expected to Reach USD 4,285.1 Million by 2020 3Health News:Global Computational Biology Market by Application (Cellular & Biological Simulation), by Services (In-house, Contract) is Expected to Reach USD 4,285.1 Million by 2020 4Health News:Global Computational Biology Market by Application (Cellular & Biological Simulation), by Services (In-house, Contract) is Expected to Reach USD 4,285.1 Million by 2020 5Health News:Global Computational Biology Market by Application (Cellular & Biological Simulation), by Services (In-house, Contract) is Expected to Reach USD 4,285.1 Million by 2020 6Health News:Harris Publications and Danny Seo Launch NATURALLY, DANNY SEO Magazine 2Health News:Harris Publications and Danny Seo Launch NATURALLY, DANNY SEO Magazine 3Health News:Harris Publications and Danny Seo Launch NATURALLY, DANNY SEO Magazine 4Health News:Harris Publications and Danny Seo Launch NATURALLY, DANNY SEO Magazine 5Health News:Harris Publications and Danny Seo Launch NATURALLY, DANNY SEO Magazine 6Health News:Blood Pressure Solution Book Review Exposes Ken Burge's Hypertension Treatment Guide – Vkool.com 2Health News:Blood Pressure Solution Book Review Exposes Ken Burge's Hypertension Treatment Guide – Vkool.com 3Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 2Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 3Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 4Health News:Nearly 60,000 Vaginal Mesh Lawsuit Claims Filed Against Seven Different Pelvic Mesh Manufacturers 5
... linked to hypertension years later, study finds , MONDAY, ... and Afghanistan who go into combat are more likely ... than those who serve in supporting roles, a new ... appeared to be a unique risk factor for newly ...
... Surging obesity rates have reversed gains, study finds , MONDAY, ... heart disease may be on the wane, experts say, with ... are now in the clear when it comes to heart ... bear much of the blame for the downturn, the researchers ...
... Analysis notes tamoxifen, raloxifene can up chances of other ... Medications given to women at high risk for developing ... drugs carry other health risks, a new analysis suggests. ... at numerous published studies, including randomized clinical trials and ...
... Global meeting ... ... Scientists and Technologists, , ,WHAT: 21st International Radon Symposium , , ,WHEN: September 20-23, ... Station, , ,WHY: Radon remains a serious, global health threat and remains the ...
... 14 Misonix, Inc. (Nasdaq: MSON ), a ... Europe is used for the ablation of tumors and worldwide ... who wishes to remain anonymous, donated the majority of the ... NM, to purchase a SonicOne(R) Ultrasonic Wound Cleansing and Debridement ...
... , LOS ALTOS, Calif., Sept. 14 ... Higgins, PhD has been named Chief Operating ... as InteKrin,s Chief Scientific Officer after joining the Company earlier ... has had increasingly broad operational and strategic responsibility in key ...
Cached Medicine News:Health News:Combat Exposure Tied to Chronic High Blood Pressure 2Health News:Most Adult Americans at Some Risk for Heart Disease 2Health News:Most Adult Americans at Some Risk for Heart Disease 3Health News:Medications That Lower Breast Cancer Risk Carry Other Dangers 2Health News:Medications That Lower Breast Cancer Risk Carry Other Dangers 3Health News:21st International Radon Symposium 2Health News:Misonix Equipment Funded By Anonymous Patient Donation 2Health News:Misonix Equipment Funded By Anonymous Patient Donation 3Health News:InteKrin Therapeutics Appoints Linda Slanec Higgins, PhD Chief Operating Officer 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: